Diego Gomez-Arbelaez1, Gregorio Sánchez-Vallejo2, Maritza Perez3, Ronald Gerardo Garcia4, Jhon Freddy Arguello5, Ernesto Peñaherrera6, Yan Carlos Duarte6, Maria Eugenia Casanova7, Jose Luis Accini8, Aristides Sotomayor9, Paul Anthony Camacho10, Patricio Lopez-Jaramillo11. 1. Fundación Oftalmológica de Santander-FOSCAL, Floridablanca, Colombia; Instituto de Investigaciones MASIRA, Facultad de Medicina, Universidad de Santander-UDES, Bucaramanga, Colombia; División de Endocrinología, Escuela de Medicina, Universidad de Santiago de Compostela, Santiago de Compostela, La Coruña, España. 2. Universidad del Quindío, Hospital San Juan de Dios, Fundación Cardiomet-Cequin, Armenia, Colombia. 3. Departamento de Medicina Interna, Universidad Militar Nueva Granada, Bogotá, Colombia. 4. Instituto de Investigaciones MASIRA, Facultad de Medicina, Universidad de Santander-UDES, Bucaramanga, Colombia; Fundación Cardiovascular de Colombia-FCV , Floridablanca, Colombia. 5. Fundación Cardiovascular de Colombia-FCV , Floridablanca, Colombia. 6. Servicio de Cardiología, Hospital Luis Vernaza, Guayaquil, Ecuador. 7. Departamento de Medicina Interna, Universidad Libre, Cali, Colombia. 8. Unidad de Cuidados Intensivos, Clínica Jaller, Universidad Libre, Barranquilla, Colombia. 9. Centro Cardiovascular Santa Lucia IPS, Cartagena, Colombia. 10. Fundación Oftalmológica de Santander-FOSCAL, Floridablanca, Colombia. 11. Fundación Oftalmológica de Santander-FOSCAL, Floridablanca, Colombia; Instituto de Investigaciones MASIRA, Facultad de Medicina, Universidad de Santander-UDES, Bucaramanga, Colombia. Electronic address: jplopezj@gmail.com.
Abstract
BACKGROUND: Alterations in glucose metabolism have been reported as risk and poor prognostic factors for acute myocardial infarction (AMI); however in Latin-American population this information is limited. Thus, an evaluation was performed on the association between glycaemic status and short- and long-term outcomes in patients with a first AMI. METHODS: A multicentre, prospective, observational, cohort study was conducted in 8 hospitals from Colombia and Ecuador. RESULTS: A total of 439 patients with confirmed AMI were included, of which 305 (69.5%) had prediabetes or type2 diabetes mellitus (DM2). Compared with normal glycaemia group, patients with known DM2 had greater risk of prolonged hospital stay (HR: 2.60, 95%CI: 1.38-4.92, P=.003), Killip class iii/iv (HR: 9.46, 95%CI: 2.20-40.62, P=.002), and in-hospital heart failure (HR: 10.76, 95%CI: 3.37-34.31, P<.001). Patients with prediabetes, new DM2, and known DM2 showed higher rates of major adverse cardiovascular events after 3years follow-up. CONCLUSION: Glucose metabolism abnormalities have an important significance in the short- and long-term prognosis in Latin-American patients that survive a first AMI.
BACKGROUND: Alterations in glucose metabolism have been reported as risk and poor prognostic factors for acute myocardial infarction (AMI); however in Latin-American population this information is limited. Thus, an evaluation was performed on the association between glycaemic status and short- and long-term outcomes in patients with a first AMI. METHODS: A multicentre, prospective, observational, cohort study was conducted in 8 hospitals from Colombia and Ecuador. RESULTS: A total of 439 patients with confirmed AMI were included, of which 305 (69.5%) had prediabetes or type2 diabetes mellitus (DM2). Compared with normal glycaemia group, patients with known DM2 had greater risk of prolonged hospital stay (HR: 2.60, 95%CI: 1.38-4.92, P=.003), Killip class iii/iv (HR: 9.46, 95%CI: 2.20-40.62, P=.002), and in-hospital heart failure (HR: 10.76, 95%CI: 3.37-34.31, P<.001). Patients with prediabetes, new DM2, and known DM2 showed higher rates of major adverse cardiovascular events after 3years follow-up. CONCLUSION:Glucose metabolism abnormalities have an important significance in the short- and long-term prognosis in Latin-American patients that survive a first AMI.
Authors: Jennifer Garay; Paul A Camacho; Jose Lopez-Lopez; Juliana Alvernia; Marcela Garcia; Daniel D Cohen; Carlos Calderon; Patricio Lopez-Jaramillo Journal: Diabetol Metab Syndr Date: 2019-12-04 Impact factor: 3.320